Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want ...

We recently published a list of Why These 15 Defensive Stocks Are Surging In 2025. In this article, we are going to take a ...

Hims & Hers Health (NYSE: HIMS) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach ...

Hims & Hers Health (NYSE: HIMS) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target ...

Hims & Hers Health ... are also likely to be motivated to add the stock following the current surge in share prices. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks ...

Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of Hims & Hers’ ...

Hims & Hers stock fell by 27% as it announced plans to stop selling commercially available compounded semaglutide. The FDA removed semaglutide from its shortage list, affecting Hims & Hers' sales ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

The stock fell more than 20% after the U.S. Food and Drug Administration removed semaglutide injections from the shortage list. Hims & Hers said that its GLP-1 offering brought in over $225 ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.